Indication
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Loading your page…
Loading your page…
Diabetes Mellitus
Marketing Authorisation Holder: Amphastar France Pharmaceuticals
EMA Authorisation: 16/12/2019
INN: glucagon
AI Drug & Interaction Analysis
Free account required
Ask Osler about Baqsimi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.